+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Breast Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

  • PDF Icon

    Report

  • 119 Pages
  • August 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5660019
Description Jump to:
This report on global breast cancer treatment market studies various drugs used for treatment of breast cancer along with pipeline analysis of upcoming potential drugs. Breast cancer is the second most common cancer observed in women worldwide, accounting for around 17% of all female cancers, making the disease exceptionally prevalent. The predictions shared by GLOBOCON in 2012 suggests that the incidence rate of breast cancer in 2012 was for ages= 65 was 503, 158 and by 2020 it is anticipated that ages=65 will be 643,442. Thus, rising incidences of breast cancer and mounting social awareness in developed and developing countries is assisting the market growth throughout the forecast period.

For the purpose of this study, the various drugs classes studied include HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptor. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.

The pipeline analysis for breast cancer treatment market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global breast cancer treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2020 to 2030 are provided in terms of USD Mn along with the respective CAGRs for the period 2022 to 2030, considering 2021 as the base year.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Breast Cancer Treatment market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Breast Cancer Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • HER2 Inhibitors
  • Trastuzumab
  • Pertuzumab
  • Ado-trastuzumab emtansine
  • Lapatinib
  • Mitotic Inhibitors
  • Eribulin
  • Docetaxel
  • Ixabepilone
  • Anti-metabolites
  • Gemcitabine
  • Aromatase Inhibitors
  • Leterozole
  • Exemestane
  • Anastrozole
  • Palbociclib
  • Everolimus
  • Hormone Receptor Antagonists
  • Goserelin Acetate
  • Fulvestrant
  • Toremifene

Key Questions Answered in this Report

  • What are the key micro and macro environmental factors that are impacting the growth of Breast Cancer Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Breast Cancer Treatment market?
  • Which is the largest regional market for Breast Cancer Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Breast Cancer Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Breast Cancer Treatment market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Breast Cancer Treatment Market
2.2. Global Breast Cancer Treatment Market, By Drug Class, 2021 (US$ Million)
2.3. Global Breast Cancer Treatment Market, By Geography, 2021 (US$ Million)
2.4. Impact of Covid 19
2.5. Attractive Investment Proposition by Geography, 2021
2.6. Competitive Analysis
2.6.1. Market Positioning of Key Breast Cancer Treatment Market Vendors
2.6.2. Strategies Adopted by Breast Cancer Treatment Market Vendors
2.6.3. Key Industry Strategies
3. Breast Cancer Treatment Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Breast Cancer Treatment Market Value, 2020 - 2030, (US$ Million)
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.2. Market Restraints
3.3.3. Key Challenges
3.3.4. Key Opportunities
3.4. Impact Analysis of Drivers and Restraints
3.5. See-Saw Analysis
3.6. Porter’s Five Force Model
3.6.1. Supplier Power
3.6.2. Buyer Power
3.6.3. Threat Of Substitutes
3.6.4. Threat Of New Entrants
3.6.5. Competitive Rivalry
3.7. PESTEL Analysis
3.7.1. Political Landscape
3.7.2. Economic Landscape
3.7.3. Technology Landscape
3.7.4. Legal Landscape
3.7.5. Social Landscape
4. Breast Cancer Treatment Market: By Drug Class, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. HER2 Inhibitors
4.3.1.1. Trastuzumab
4.3.1.2. Pertuzumab
4.3.1.3. Ado-trastuzumab emtansine
4.3.1.4. Lapatinib
4.3.2. Mitotic Inhibitors
4.3.2.1. Eribulin
4.3.2.2. Docetaxel
4.3.2.3. Ixabepilone
4.3.3. Anti-metabolites
4.3.3.1. Gemcitabine
4.3.4. Aromatase Inhibitors
4.3.4.1. Leterozole
4.3.4.2. Exemestane
4.3.4.3. Anastrozole
4.3.4.4. Palbociclib
4.3.4.5. Everolimus
4.3.5. Hormone Receptor Antagonists
4.3.5.1. Goserelin Acetate
4.3.5.2. Fulvestrant
4.3.5.3. Toremifene
5. North America Breast Cancer Treatment Market, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Breast Cancer Treatment Market: By Drug Class, 2020-2030, USD (Million)
5.3.Breast Cancer Treatment Market: By Region, 2020-2030, USD (Million)
5.3.1.North America
5.3.1.1. U.S.
5.3.1.2. Canada
5.3.1.3. Rest of North America
6. UK and European Union Breast Cancer Treatment Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Breast Cancer Treatment Market: By Drug Class, 2020-2030, USD (Million)
6.3.Breast Cancer Treatment Market: By Region, 2020-2030, USD (Million)
6.3.1.UK and European Union
6.3.1.1. UK
6.3.1.2. Germany
6.3.1.3. Spain
6.3.1.4. Italy
6.3.1.5. France
6.3.1.6. Rest of Europe
7. Asia Pacific Breast Cancer Treatment Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Breast Cancer Treatment Market: By Drug Class, 2020-2030, USD (Million)
7.3.Breast Cancer Treatment Market: By Region, 2020-2030, USD (Million)
7.3.1.Asia Pacific
7.3.1.1. China
7.3.1.2. Japan
7.3.1.3. India
7.3.1.4. Australia
7.3.1.5. South Korea
7.3.1.6. Rest of Asia Pacific
8. Latin America Breast Cancer Treatment Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Breast Cancer Treatment Market: By Drug Class, 2020-2030, USD (Million)
8.3.Breast Cancer Treatment Market: By Region, 2020-2030, USD (Million)
8.3.1.Latin America
8.3.1.1. Brazil
8.3.1.2. Mexico
8.3.1.3. Rest of Latin America
9. Middle East and Africa Breast Cancer Treatment Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Breast Cancer Treatment Market: By Drug Class, 2020-2030, USD (Million)
9.3.Breast Cancer Treatment Market: By Region, 2020-2030, USD (Million)
9.3.1.Middle East and Africa
9.3.1.1. GCC
9.3.1.2. Africa
9.3.1.3. Rest of Middle East and Africa
10. Company Profile
10.1. AstraZeneca plc
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Portfolio
10.1.4. Strategic Initiatives
10.2. Eisai Co., Ltd.
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.4. Strategic Initiatives
10.3. Eli Lilly and Company
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.4. Strategic Initiatives
10.4. F. Hoffmann-La Roche Ltd.
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Portfolio
10.4.4. Strategic Initiatives
10.5. GlaxoSmithKline plc
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Portfolio
10.5.4. Strategic Initiatives
10.6. Novartis International AG
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.4. Strategic Initiatives
10.7. Pfizer, Inc.
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Portfolio
10.7.4. Strategic Initiatives
10.8. Puma Biotechnology, Inc.
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.4. Strategic Initiatives
10.9. Sanofi S.A.
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Portfolio
10.9.4. Strategic Initiatives
10.10. Teva Pharmaceutical Industries Ltd.
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Portfolio
10.10.4. Strategic Initiatives
List of Figures
Figure 1 Global Breast Cancer Treatment Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Breast Cancer Treatment Market: Quality Assurance
Figure 5 Global Breast Cancer Treatment Market, By Drug Class, 2021
Figure 6 Global Breast Cancer Treatment Market, By Geography, 2021
Figure 7 Global Breast Cancer Treatment Market, By Drug Class, 2021 Vs 2030, %
Figure 8 U.S. Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 9 Canada Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 10 Rest of North America Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 11 UK Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 12 Germany Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 13 Spain Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 14 Italy Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 15 France Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 16 Rest of Europe Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 17 China Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 18 Japan Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 19 India Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 20 Australia Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 21 South Korea Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 22 Rest of Asia Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 23 Brazil Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 24 Mexico Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 25 Rest of Latin America Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 26 GCC Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 27 Africa Breast Cancer Treatment Market (US$ Million), 2020 - 2030
Figure 28 Rest of Middle East and Africa Breast Cancer Treatment Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Breast Cancer Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 2 Global Breast Cancer Treatment Market By HER2 Inhibitors, 2020-2030, USD (Million)
Table 3 Global Breast Cancer Treatment Market By Mitotic Inhibitors, 2020-2030, USD (Million)
Table 4 Global Breast Cancer Treatment Market By Anti-metabolites, 2020-2030, USD (Million)
Table 5 Global Breast Cancer Treatment Market By Aromatase Inhibitors, 2020-2030, USD (Million)
Table 6 Global Breast Cancer Treatment Market By Hormone Receptor Antagonists, 2020-2030, USD (Million)
Table 7 North America Breast Cancer Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 8 North America Breast Cancer Treatment Market By HER2 Inhibitors, 2020-2030, USD (Million)
Table 9 North America Breast Cancer Treatment Market By Mitotic Inhibitors, 2020-2030, USD (Million)
Table 10 North America Breast Cancer Treatment Market By Anti-metabolites, 2020-2030, USD (Million)
Table 11 North America Breast Cancer Treatment Market By Aromatase Inhibitors, 2020-2030, USD (Million)
Table 12 North America Breast Cancer Treatment Market By Hormone Receptor Antagonists, 2020-2030, USD (Million)
Table 13 UK and European Union Breast Cancer Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 14 UK and European Union Breast Cancer Treatment Market By HER2 Inhibitors, 2020-2030, USD (Million)
Table 15 UK and European Union Breast Cancer Treatment Market By Mitotic Inhibitors, 2020-2030, USD (Million)
Table 16 UK and European Union Breast Cancer Treatment Market By Anti-metabolites, 2020-2030, USD (Million)
Table 17 UK and European Union Breast Cancer Treatment Market By Aromatase Inhibitors, 2020-2030, USD (Million)
Table 18 UK and European Union Breast Cancer Treatment Market By Hormone Receptor Antagonists, 2020-2030, USD (Million)
Table 19 Asia Pacific Breast Cancer Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 20 Asia Pacific Breast Cancer Treatment Market By HER2 Inhibitors, 2020-2030, USD (Million)
Table 21 Asia Pacific Breast Cancer Treatment Market By Mitotic Inhibitors, 2020-2030, USD (Million)
Table 22 Asia Pacific Breast Cancer Treatment Market By Anti-metabolites, 2020-2030, USD (Million)
Table 23 Asia Pacific Breast Cancer Treatment Market By Aromatase Inhibitors, 2020-2030, USD (Million)
Table 24 Asia Pacific Breast Cancer Treatment Market By Hormone Receptor Antagonists, 2020-2030, USD (Million)
Table 25 Latin America Breast Cancer Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 26 Latin America Breast Cancer Treatment Market By HER2 Inhibitors, 2020-2030, USD (Million)
Table 27 Latin America Breast Cancer Treatment Market By Mitotic Inhibitors, 2020-2030, USD (Million)
Table 28 Latin America Breast Cancer Treatment Market By Anti-metabolites, 2020-2030, USD (Million)
Table 29 Latin America Breast Cancer Treatment Market By Aromatase Inhibitors, 2020-2030, USD (Million)
Table 30 Latin America Breast Cancer Treatment Market By Hormone Receptor Antagonists, 2020-2030, USD (Million)
Table 31 Middle East and Africa Breast Cancer Treatment Market By Drug Class, 2020-2030, USD (Million)
Table 32 Middle East and Africa Breast Cancer Treatment Market By HER2 Inhibitors, 2020-2030, USD (Million)
Table 33 Middle East and Africa Breast Cancer Treatment Market By Mitotic Inhibitors, 2020-2030, USD (Million)
Table 34 Middle East and Africa Breast Cancer Treatment Market By Anti-metabolites, 2020-2030, USD (Million)
Table 35 Middle East and Africa Breast Cancer Treatment Market By Aromatase Inhibitors, 2020-2030, USD (Million)
Table 36 Middle East and Africa Breast Cancer Treatment Market By Hormone Receptor Antagonists, 2020-2030, USD (Million)

Companies Mentioned

  • AstraZeneca plc
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Related Topics

Related Reports

Breast Cancer Drugs Market by Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Breast Cancer Drugs Market by Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Breast Cancer Drugs Global Market Report 2024 - Product Image

Breast Cancer Drugs Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

HER2-Negative Breast Cancer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 200 Pages
  • Global
Estrogen Receptor Positive Breast Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Estrogen Receptor Positive Breast Cancer Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End-use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 110 Pages
  • Global
From
HER2-Negative Breast Cancer - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

HER2-Negative Breast Cancer - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.